Non-gastric Marginal Zone B-cell Lymphoma in Korea: Clinical Features, Treatment, and Prognostic Factors.
10.3904/kjim.2010.25.3.227
- Author:
Sung Yong OH
1
;
Cheolwon SUH
Author Information
1. Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
- Publication Type:Review ; Research Support, Non-U.S. Gov't
- Keywords:
Lymphoma, B-cell, marginal zone;
Korea
- MeSH:
Humans;
Korea;
Lymphoma, B-Cell, Marginal Zone/*diagnosis/*therapy;
Neoplasm Staging;
Organ Specificity;
Prognosis;
Splenic Neoplasms/diagnosis/therapy
- From:The Korean Journal of Internal Medicine
2010;25(3):227-236
- CountryRepublic of Korea
- Language:English
-
Abstract:
Marginal zone B-cell lymphoma (MZL) is the second most common subtype of non-Hodgkin's lymphoma in Korea (17.3%). Mucosa-associated lymphoid tissue (MALT) can develop in almost any organ as a result of exposure to a persistent stimulus, such as chronic infection or certain autoimmune processes. Under conditions of prolonged lymphoid proliferation, a malignant clone may emerge, which is followed by the development of a MALT lymphoma. Whereas MALT lymphoma of the stomach is the most common and the most extensively studied, we focus on non-gastric MZL studies conducted in Korea that highlight the most recent advances with respect to MZL definition, etiology, clinical characteristics, natural history, treatment approaches, outcomes, and prognostic factors. Moreover, we discuss current organ-specific considerations and controversies, and identify areas for future research.
